Sore Throat News and Research RSS Feed - Sore Throat News and Research

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. [More]
Guidelines for staying healthy during flu season

Guidelines for staying healthy during flu season

The American Academy of Pediatrics updated its annual influenza (flu) season guidelines, withdrawing the child-friendly nasal flu vaccine, FluMist, this year. [More]
FDA approves novel stomach-draining device to treat obesity

FDA approves novel stomach-draining device to treat obesity

The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal. [More]
Study estimates 30% of outpatient oral antibiotic prescription in the U.S as inappropriate

Study estimates 30% of outpatient oral antibiotic prescription in the U.S as inappropriate

An estimated 30 percent of outpatient oral antibiotic prescriptions in the U.S. in 2010-2011 may have been inappropriate, findings that support the need for establishing a goal for outpatient antibiotic stewardship, according to a study appearing in the May 3 issue of JAMA. [More]
New KidsMD Alexa skill device allows parents to get easier to access medical information

New KidsMD Alexa skill device allows parents to get easier to access medical information

"My child has a fever of 101. Should I be concerned?" Through a new skill created for Amazon Alexa-enabled devices, parents will now be able to ask Alexa a variety of questions around fever and other common symptoms. The KidsMD Alexa skill was developed by the Innovation & Digital Health Accelerator team at Boston Children's Hospital and launched today. [More]
Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. [More]
Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Mycoplasma pneumoniae infections began rising in Beijing last spring, and by December, this pathogen was found in more than half of hospitalized children suffering from pneumonia in that city, according to investigators from the Capital Institute of Pediatrics, Beijing, China. [More]
Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids. [More]
Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical

Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical

An analysis of 145 different electronic-cigarette flavoring products reveals that many e-cigarette users may be exposed to a potentially harmful chemical. In a research letter published online today in the peer-reviewed journal Thorax, a research team led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute reports that high levels of the respiratory irritant benzaldehyde were detected in the vapor from most of the flavored nicotine products they studied, with the highest concentrations in vapor from cherry-flavored products. [More]
Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim. [More]
SLU infectious diseases experts answer flu season questions

SLU infectious diseases experts answer flu season questions

A cure for the common cold isn't in the crystal ball of an infectious diseases researcher and physician at Saint Louis University's Center for Vaccine Development. [More]
Shared decision making between doctors and patients useful in fight against antibiotic resistance

Shared decision making between doctors and patients useful in fight against antibiotic resistance

A new Cochrane Review published today shows that when doctors and patients are encouraged to discuss the need for prescribing antibiotics for acute respiratory infections jointly, fewer are prescribed. This may be useful in the fight against antibiotic resistance. [More]
Researchers track re-emergence of scarlet fever-causing bacteria

Researchers track re-emergence of scarlet fever-causing bacteria

An international study led by University of Queensland researchers has tracked the re-emergence of a childhood disease which had largely disappeared over the past 100 years. [More]
Johns Hopkins doctors urge people to get vaccinated against influenza virus

Johns Hopkins doctors urge people to get vaccinated against influenza virus

Flu season is upon us again — and yes, you should get the flu vaccine. Doctors at the Johns Hopkins University School of Medicine say everyone 6 months of age and older should get vaccinated against the influenza virus this year. [More]
Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD. [More]
Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States. [More]
FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen. [More]
Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab. [More]
Air pollution from forest fires aggravates children’s respiratory health

Air pollution from forest fires aggravates children’s respiratory health

Research coordinated by lecturer of the Faculty of Nursing at the University of Valencia Ferran Ballester has shown that air pollution from forest fires aggravates the respiratory health of children. [More]
Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Individuals who received the flu vaccine were protected for up to 6 months post-vaccination, the duration of most flu seasons, according to a study presented at the 2015 International Conference on Emerging Infectious Diseases. [More]
Advertisement
Advertisement